全球首款尿路上皮癌靶向药-厄达替尼

Urothelial carcinoma (UC) refers to the epithelial structure from the kidney outlet to the urethra. Once a tumor occurs, it is called urothelial carcinoma. Common ones include bladder cancer, ureteral cancer, renal pelvis cancer, etc. 90% to 95% of bladder malignant tumors are UC, and the remaining 5% to 10% are mesenchymal tumors and other rare epithelial tumors. (erdafitinib) was jointly discovered by Astex Pharmaceuticals of the United States and Janssen Biotechnology, a subsidiary of the Johnson & Johnson Pharmaceutical Group, in June 2008 as a new drug for the treatment of adult urothelial cancer. Erdafitinib is also the world’s first targeted drug for urothelial cancer.

Erdafitinib is also translated as Erdatinib. On April 12, 2019, the U.S. FDA granted accelerated approval to the oral small molecule pan-FGFR inhibitor erdafitinib from Janssen, a subsidiary of Johnson & Johnson, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who carry FGFR2/3 mutations or fusions and have disease progression during or after platinum-based chemotherapy (including within one year of neoadjuvant chemotherapy or adjuvant chemotherapy).

Clinical trials have shown remarkable results in the treatment of urothelial carcinoma, but erdafitinib can cause central serous retinopathy or retinal pigment epithelial detachment. Clinical symptoms include blurred vision, visual floaters, or visual fatigue. The incidence rate is 25% (Grade 3, 3%). The median onset time is 50 days. 13% of patients are in remission, and 13% of patients still suffer from the disease by the clinical cutoff. Erdafitinib was suspended in 9% of patients, reduced in 14% of patients, and permanently discontinued in 3% of patients.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: